274 related articles for article (PubMed ID: 23353876)
1. Is basic research providing answers if adjuvant anti-estrogen treatment of breast cancer can induce cognitive impairment?
Buwalda B; Schagen SB
Life Sci; 2013 Oct; 93(17):581-8. PubMed ID: 23353876
[TBL] [Abstract][Full Text] [Related]
2. Vascular effects of aromatase inhibitors: data from clinical trials.
Howell A; Cuzick J
J Steroid Biochem Mol Biol; 2005 May; 95(1-5):143-9. PubMed ID: 15936188
[TBL] [Abstract][Full Text] [Related]
3. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Baumann CK; Castiglione-Gertsch M
Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
[TBL] [Abstract][Full Text] [Related]
4. Cognitive limitations associated with tamoxifen and aromatase inhibitors in employed breast cancer survivors.
Breckenridge LM; Bruns GL; Todd BL; Feuerstein M
Psychooncology; 2012 Jan; 21(1):43-53. PubMed ID: 20967847
[TBL] [Abstract][Full Text] [Related]
5. Effects of hormonal therapy on cognitive functioning in breast cancer patients: a review of the literature.
Schilder CM; Schagen SB
Minerva Ginecol; 2007 Aug; 59(4):387-401. PubMed ID: 17923830
[TBL] [Abstract][Full Text] [Related]
6. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen.
Castellon SA; Ganz PA; Bower JE; Petersen L; Abraham L; Greendale GA
J Clin Exp Neuropsychol; 2004 Oct; 26(7):955-69. PubMed ID: 15742545
[TBL] [Abstract][Full Text] [Related]
7. [Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
Tuxen MK; Nielsen DL; Lindberg H; Kamby C
Ugeskr Laeger; 2007 Jan; 169(4):297-9. PubMed ID: 17274922
[TBL] [Abstract][Full Text] [Related]
8. The influence of endocrine treatments for breast cancer on health-related quality of life.
Buijs C; de Vries EG; Mourits MJ; Willemse PH
Cancer Treat Rev; 2008 Nov; 34(7):640-55. PubMed ID: 18514425
[TBL] [Abstract][Full Text] [Related]
9. Adherence to long-term adjuvant hormonal therapy for breast cancer.
Gotay C; Dunn J
Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):709-15. PubMed ID: 22098287
[TBL] [Abstract][Full Text] [Related]
10. Short-term effects of treatment-induced hormonal changes on cognitive function in breast cancer patients: results of a multicenter, prospective, longitudinal study.
Hermelink K; Henschel V; Untch M; Bauerfeind I; Lux MP; Munzel K
Cancer; 2008 Nov; 113(9):2431-9. PubMed ID: 18823033
[TBL] [Abstract][Full Text] [Related]
11. Cognitive Deficits in Breast Cancer Survivors After Chemotherapy and Hormonal Therapy.
Frank JS; Vance DE; Triebel KL; Meneses KM
J Neurosci Nurs; 2015 Dec; 47(6):302-12. PubMed ID: 26447567
[TBL] [Abstract][Full Text] [Related]
12. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
Gradishar WJ
Oncology; 2005; 69(1):1-9. PubMed ID: 16088229
[TBL] [Abstract][Full Text] [Related]
13. Cognitive changes associated with endocrine therapy for breast cancer.
Agrawal K; Onami S; Mortimer JE; Pal SK
Maturitas; 2010 Nov; 67(3):209-14. PubMed ID: 20688441
[TBL] [Abstract][Full Text] [Related]
14. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
Mouridsen HT
Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
[TBL] [Abstract][Full Text] [Related]
15. The effects of adjuvant endocrine therapy on bone health in women with breast cancer.
Ramchand SK; Cheung YM; Yeo B; Grossmann M
J Endocrinol; 2019 Jun; 241(3):R111-R124. PubMed ID: 30991355
[TBL] [Abstract][Full Text] [Related]
16. Aromatase inhibitors and cardiac toxicity: getting to the heart of the matter.
Gandhi S; Verma S
Breast Cancer Res Treat; 2007 Nov; 106(1):1-9. PubMed ID: 17211535
[TBL] [Abstract][Full Text] [Related]
17. Molecularly targeted endocrine therapies for breast cancer.
Orlando L; Schiavone P; Fedele P; Calvani N; Nacci A; Rizzo P; Marino A; D'Amico M; Sponziello F; Mazzoni E; Cinefra M; Fazio N; Maiello E; Silvestris N; Colucci G; Cinieri S
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S67-71. PubMed ID: 21129614
[TBL] [Abstract][Full Text] [Related]
18. Cognitive impairment associated with adjuvant therapy in breast cancer.
Bender CM; Sereika SM; Berga SL; Vogel VG; Brufsky AM; Paraska KK; Ryan CM
Psychooncology; 2006 May; 15(5):422-30. PubMed ID: 16097037
[TBL] [Abstract][Full Text] [Related]
19. Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies.
Johnston SR
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4376s-4387s; discussion 4411s-4412s. PubMed ID: 11916228
[TBL] [Abstract][Full Text] [Related]
20. Aromatase inhibitors and breast cancer prevention.
Litton JK; Arun BK; Brown PH; Hortobagyi GN
Expert Opin Pharmacother; 2012 Feb; 13(3):325-31. PubMed ID: 22242911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
